AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 145 filers reported holding AGIOS PHARMACEUTICALS INC in Q4 2014. The put-call ratio across all filers is 1.31 and the average weighting 1.0%.
Links
Filings
- All filings
- Annual reports (10-K)
- Quarterly reports (10-Q)
- Insider transactions
- Shareholder votes
- Significant ownership
- Events
EDGAR links
External links
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,146,935 | -17.1% | 248,361 | -5.2% | 0.00% | 0.0% |
| Q2 2023 | $7,416,187 | +19.7% | 261,871 | -2.9% | 0.00% | 0.0% |
| Q1 2023 | $6,197,719 | +8764.1% | 269,818 | +10736.1% | 0.00% | – |
| Q4 2022 | $69,919 | -43.6% | 2,490 | -43.7% | 0.00% | – |
| Q3 2022 | $124,000 | +11.7% | 4,423 | -10.8% | 0.00% | – |
| Q2 2022 | $111,000 | -89.3% | 4,960 | -86.0% | 0.00% | – |
| Q1 2022 | $1,033,000 | -40.7% | 35,463 | -33.0% | 0.00% | – |
| Q4 2021 | $1,741,000 | -49.2% | 52,969 | -28.7% | 0.00% | -100.0% |
| Q3 2021 | $3,428,000 | -9.7% | 74,279 | +7.8% | 0.00% | 0.0% |
| Q2 2021 | $3,798,000 | -41.6% | 68,918 | -45.3% | 0.00% | 0.0% |
| Q1 2021 | $6,501,000 | -20.3% | 125,889 | -33.2% | 0.00% | -50.0% |
| Q4 2020 | $8,161,000 | +59.6% | 188,329 | +28.9% | 0.00% | +100.0% |
| Q3 2020 | $5,113,000 | -42.5% | 146,056 | -12.2% | 0.00% | -66.7% |
| Q2 2020 | $8,894,000 | +65.5% | 166,333 | +9.8% | 0.00% | +50.0% |
| Q1 2020 | $5,374,000 | -9.8% | 151,439 | +21.4% | 0.00% | 0.0% |
| Q4 2019 | $5,956,000 | +65.5% | 124,723 | +12.3% | 0.00% | +100.0% |
| Q3 2019 | $3,599,000 | -37.8% | 111,095 | -4.2% | 0.00% | -50.0% |
| Q2 2019 | $5,787,000 | -26.6% | 116,015 | -0.7% | 0.00% | 0.0% |
| Q1 2019 | $7,880,000 | +17.9% | 116,845 | -19.4% | 0.00% | 0.0% |
| Q4 2018 | $6,685,000 | -87.9% | 144,973 | -81.6% | 0.00% | -87.5% |
| Q3 2018 | $55,093,000 | +60.6% | 787,353 | +93.3% | 0.02% | +60.0% |
| Q2 2018 | $34,315,000 | +476.5% | 407,393 | +459.8% | 0.01% | +400.0% |
| Q1 2018 | $5,952,000 | +46.5% | 72,776 | +2.4% | 0.00% | +100.0% |
| Q4 2017 | $4,063,000 | -33.1% | 71,065 | -21.9% | 0.00% | -50.0% |
| Q3 2017 | $6,073,000 | +23.6% | 90,989 | -4.8% | 0.00% | 0.0% |
| Q2 2017 | $4,915,000 | +110.0% | 95,547 | +138.4% | 0.00% | +100.0% |
| Q1 2017 | $2,341,000 | +476.6% | 40,084 | +312.0% | 0.00% | – |
| Q4 2016 | $406,000 | +19.8% | 9,730 | +52.1% | 0.00% | – |
| Q3 2016 | $339,000 | -42.2% | 6,399 | -54.3% | 0.00% | – |
| Q2 2016 | $586,000 | 0.0% | 13,996 | -2.9% | 0.00% | – |
| Q1 2016 | $586,000 | -34.0% | 14,415 | +5.3% | 0.00% | – |
| Q4 2015 | $888,000 | +125.4% | 13,689 | +145.3% | 0.00% | – |
| Q3 2015 | $394,000 | -50.1% | 5,580 | -21.6% | 0.00% | – |
| Q2 2015 | $790,000 | +20.8% | 7,116 | +2.8% | 0.00% | – |
| Q1 2015 | $654,000 | +207.0% | 6,924 | +264.6% | 0.00% | – |
| Q4 2014 | $213,000 | +163.0% | 1,899 | +43.5% | 0.00% | – |
| Q3 2014 | $81,000 | +20.9% | 1,323 | -9.8% | 0.00% | – |
| Q2 2014 | $67,000 | +131.0% | 1,466 | +101.4% | 0.00% | – |
| Q1 2014 | $29,000 | +383.3% | 728 | +188.9% | 0.00% | – |
| Q4 2013 | $6,000 | -87.2% | 252 | -85.0% | 0.00% | – |
| Q3 2013 | $47,000 | – | 1,675 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Eagle Health Investments LP | 431,413 | $12,558,000 | 3.09% |
| Casdin Capital, LLC | 2,090,000 | $60,840,000 | 2.73% |
| Rock Springs Capital Management LP | 2,665,275 | $77,586,000 | 1.95% |
| Bellevue Group AG | 4,129,292 | $120,204,000 | 1.40% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,177,374 | $34,273,000 | 1.05% |
| Altium Capital Management LP | 66,196 | $1,927,000 | 0.64% |
| ArrowMark Colorado Holdings LLC | 1,295,948 | $37,725,000 | 0.33% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,333,012 | $38,804,000 | 0.19% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 21,500 | $707,000 | 0.16% |
| Virtus ETF Advisers LLC | 11,541 | $336,000 | 0.15% |